News Sentiment

LFCR sentiment intelligence

Lifecore Biomedical Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 4.75 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-6.7% over one week, -15.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

New Lifecore Hire Gets 3,500 Stock Units Vesting in Three Years

Market Reaction

Price moving ahead of tone

59/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction -6.7% Price reacting lower
Trend fit Trend inactive -15.8% over four weeks
Fair value -28.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 36
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Market source 6
Stock Titan 5
GlobeNewswire 5
Quartr 4
TradingKey 4
MT Newswires 3
simplywall.st 3

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 14
Deals and strategy 4
Analyst action 4
Regulatory and legal 3
Balance sheet 2
Guidance 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
Quartr Direct company coverage

Lifecore Biomedical (LFCR) Proxy filing Summary

Lifecore Biomedical's 2026 annual meeting, scheduled for June 4, 2026, will address four key proposals including the election of nine directors, ratification of KPMG LLP as auditor, advisory approval of executive compensation, and the 2026 Stock Incentive Plan. Holders of Common

Tone
Neutral 50/100
Event
Regulatory and legal
Published
14 Jul 2026 10:14
Source
Quartr
Quartr Direct company coverage

Lifecore Biomedical (LFCR) Q2 2024 earnings summary

Lifecore Biomedical (LFCR) reported strong Q2 FY2024 earnings, with total revenues up 38% year-over-year to $30.2M and a net income of $14.2M, compared to a net loss in the prior year. The company has transitioned to a pure-play CDMO, focusing on sterile injectable pharmaceutical

Tone
Positive 73/100
Event
Earnings
Published
14 Jul 2026 07:16
Source
Quartr
Quartr Direct company coverage

Lifecore Biomedical (LFCR) Q1 2026 earnings summary

Lifecore Biomedical reported its Q1 2026 earnings with revenue down 34% year-over-year to $23.2 million and a net loss of $15.0 million. Despite the decline, the company saw a 52% reduction in operating expenses and signed three new commercial site transfer programs. Lifecore rea

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 07:14
Source
Quartr
Quartr Direct company coverage

Lifecore Biomedical (LFCR) Q3 2024 earnings summary

Lifecore Biomedical (LFCR) reported a strong Q3 FY24, with total revenues rising 35% year-over-year to $35.7M and net income reaching $15.6M, a significant improvement from a net loss in the prior year. The company has transitioned to a pure-play CDMO focusing on sterile injectab

Tone
Positive 75/100
Event
Earnings
Published
14 Jul 2026 02:14
Source
Quartr
Moomoo Direct company coverage

Lifecore Biomedical (LFCR) Stock Forum and Discussion

This document appears to be a placeholder or an incomplete article about Lifecore Biomedical (LFCR). It is titled "Lifecore Biomedical (LFCR) Stock Forum and Discussion" but contains no substantive content.

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 18:10
Source
Moomoo
Stock Titan Direct company coverage

[SCHEDULE 13D/A] LIFECORE BIOMEDICAL, INC. \DE\ Amended Major Shareholder Report

This SCHEDULE 13D/A filing for Lifecore Biomedical, Inc. (LFCR) details an amended major shareholder report by 22NW Fund, LP and related entities. It specifies that 22NW Fund, LP beneficially owns 2,712,472 shares, representing 6.74% of the outstanding common stock, including con

Tone
Negative 36/100
Event
Market update
Published
03 Jul 2026 03:39
Source
Stock Titan
Stock Titan Direct company coverage

Legion Partners (LFCR) reports 17.1% stake and seeks cash redemption of Lifecore preferred

Legion Partners and its affiliates have reported a significant 17.1% stake in Lifecore Biomedical (LFCR) through a recent SEC filing. The filing indicates beneficial ownership of up to 6,794,595 common shares on an as-converted basis, including shares from immediately convertible

Tone
Neutral 50/100
Event
Deals and strategy
Published
03 Jul 2026 03:10
Source
Stock Titan
Stock Titan Direct company coverage

Lifecore Biomedical (NASDAQ: LFCR) gets $52.1M preferred redemption requests

Lifecore Biomedical has received redemption notices for all outstanding shares of its Series A Redeemable Convertible Preferred Stock, requiring a $52.1 million cash redemption by December 28, 2026. The company's current liquidity of $38.1 million is less than the redemption amou

Tone
Negative 29/100
Event
Balance sheet
Published
02 Jul 2026 21:10
Source
Stock Titan
TradingView Direct company coverage

Lifecore Biomedical faces $52.1M Series A preferred redemption due Dec. 28, 2026

Lifecore Biomedical announced a $52.1 million redemption obligation due December 28, 2026, stemming from notices to redeem all 49,263 shares of its Series A preferred stock. The total payout includes a liquidation value of approximately $50.2 million and $0.9 million in accrued d

Tone
Negative 20/100
Event
Market update
Published
02 Jul 2026 21:10
Source
TradingView
Simply Wall Street Direct company coverage

Is Now An Opportune Moment To Examine Lifecore Biomedical, Inc. (NASDAQ:LFCR)?

Lifecore Biomedical, Inc. (LFCR) has seen a significant price increase but is currently overvalued by about 30% according to Simply Wall St's valuation model, trading at US$4.96 against an intrinsic value of $3.82. The company is expected to have highly negative earnings growth,

Tone
Negative 37/100
Event
Earnings
Published
30 Jun 2026 10:10
Source
Simply Wall Street
The National Law Review Direct company coverage

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing at Lifecore Biomedical, Inc. (LFCR). The firm is encouraging investors who purchased Lifecore securities before October 7, 2020, and still hold them, to contact them for more info

Tone
Negative 26/100
Event
Regulatory and legal
Published
29 Jun 2026 14:40
Source
The National Law Review
TradingView Direct company coverage

Price to book forward of Lifecore Biomedical, Inc. – NASDAQ:LFCR

This article presents the "Price to book forward" financial metric for Lifecore Biomedical, Inc. (NASDAQ: LFCR). It is a brief data point provided by TradingView, with no additional analytical content.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 13:43
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Lifecore Biomedical, Inc. – NASDAQ:LFCR

This page provides financial information for Lifecore Biomedical, Inc. (NASDAQ: LFCR), focusing on its enterprise value to revenue forward. The content is hosted on TradingView, a financial platform offering various market data and analysis tools. It appears to be a snapshot or a

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 06:39
Source
TradingView
The National Law Review Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. (NASDAQ: LFCR) who bought securities prior to October 7, 2020, and still hold them. The investigation aims to determine if Lifecore's officers and/or director

Tone
Negative 18/100
Event
Regulatory and legal
Published
28 Jun 2026 06:11
Source
The National Law Review
TradingView Direct company coverage

Price to sales forward of Lifecore Biomedical, Inc. – SWB:LDE

The article displays the "Price to sales forward" metric for Lifecore Biomedical, Inc. (SWB:LDE) on the Stuttgart Stock Exchange. It indicates that the market is closed with no trades recorded and provides financial data and other market information.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 04:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Lifecore Biomedical, Inc. – LSX:899376

This article provides financial information for Lifecore Biomedical, Inc. (LSX:899376), specifically focusing on its price-to-sales forward metric. The data is presented via TradingView, which aggregates market and reference data from various sources like ICE Data Services and Fa

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 21:10
Source
TradingView
TradingView Direct company coverage

Lifecore Biomedical, Inc. Actuals & Estimates (NASDAQ:LFCR)

This article provides an overview of Lifecore Biomedical, Inc. (NASDAQ: LFCR) stock, including its current price, performance trends, and analyst forecasts. It details financial actuals and estimates for income, balance sheet, and cash flow, along with frequently asked questions

Tone
Negative 38/100
Event
Analyst action
Published
27 Jun 2026 19:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Lifecore Biomedical, Inc. – NASDAQ:LFCR

This article provides financial information for Lifecore Biomedical, Inc. (NASDAQ: LFCR), specifically focusing on its forward price-to-earnings ratio. It seems to be a placeholder or snapshot from a financial platform, showing that there are no current trades and directing users

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 09:39
Source
TradingView
TradingView Direct company coverage

LFCR Forecast — Price Target — Prediction for 2027

This article provides an overview of Lifecore Biomedical, Inc. (LFCR) stock, including its current price, analyst forecasts, and financial data. Analysts predict a maximum price of $9.00 and a minimum of $5.00 for LFCR. The article also covers historical price performance, volati

Tone
Neutral 50/100
Event
Analyst action
Published
27 Jun 2026 01:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Lifecore Biomedical, Inc. – NASDAQ:LFCR

This article displays the forward Enterprise Value to EBIT for Lifecore Biomedical, Inc. (NASDAQ: LFCR). It is a financial data point presented by TradingView, indicating the company's valuation relative to its expected operating earnings. The information is provided without furt

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 17:40
Source
TradingView
TradingView Direct company coverage

Lifecore Biomedical, Inc. Actuals & Estimates (BOATS:LFCR)

This article provides financial actuals and estimates for Lifecore Biomedical, Inc. (LFCR) on the BOATS exchange, including analyst forecasts, historical stock prices, and upcoming earnings dates. It details the company's past quarterly earnings and revenue, noting that LFCR does

Tone
Negative 39/100
Event
Earnings
Published
26 Jun 2026 12:39
Source
TradingView
TradingView Direct company coverage

Lifecore Biomedical, Inc. Actuals & Estimates (GETTEX:LDE)

Lifecore Biomedical, Inc. (GETTEX:LDE) stock is currently trading at 4.58 EUR, having decreased by 4.98% in the past 24 hours. The company's market capitalization is 177.81 million EUR, and analysts have a price target range of 4.31 EUR to 7.77 EUR for the stock. Lifecore is set

Tone
Negative 39/100
Event
Analyst action
Published
26 Jun 2026 12:11
Source
TradingView
TradingView Direct company coverage

LDE Forecast — Price Target — Prediction for 2027

This article provides a forecast for Lifecore Biomedical, Inc. (LDE) stock, including analyst price targets and ratings. It details recent stock performance, financial metrics like EPS and revenue, and answers common questions about the company's stock, market capitalization, ear

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 07:10
Source
TradingView
TradingKey Direct company coverage

Lifecore Biomedical Inc (LFCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Lifecore Biomedical Inc (LFCR) focusing on its stock resistance, support levels, and various technical indicators. The current price momentum score is 8.18, suggesting the stock is suitable for range-bound swing trading between $5.07

Tone
Negative 19/100
Event
Market update
Published
23 Jun 2026 00:10
Source
TradingKey
TradingKey Direct company coverage

Lifecore Biomedical Inc (LFCR) Institutional Confidence

The article details the institutional confidence level in Lifecore Biomedical Inc (LFCR), noting its score of 7.00, placing it 51st out of 157 in the Pharmaceuticals industry. The institutional shareholding proportion has increased to 81.48%, with ETHSX being the largest sharehol

Tone
Positive 71/100
Event
Market update
Published
22 Jun 2026 23:10
Source
TradingKey
Stock Traders Daily Direct company coverage

How (LFCR) Movements Inform Risk Allocation Models

This article provides an in-depth analysis of Lifecore Biomedical Inc. (LFCR) using AI models, highlighting a 66.5:1 risk-reward setup targeting a 24.8% gain. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, o

Tone
Neutral 50/100
Event
Market update
Published
21 Jun 2026 04:10
Source
Stock Traders Daily